Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Debiopharm Ink Biomarker ID Deal

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix's expertise in combining high-throughput screening with high-content assays in cultured human cells will be applied to identify predictive biomarkers for Debiopharm's preclinical cancer candidates. Cenix has established multiparametric microscopy-based readouts using the Definiens XD image analysis platform, which will be used in human cancer cell models to identify genes and pathways that enhance or suppress a drug's therapeutic effects.

According to the partners, "the study represents another important illustration of Debiopharm's ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach toward the development of new therapeutics."

Financial and other terms of the deal were not disclosed.

Cenix is a preclinical contract research organization with operations in Germany, Belgium, and the US and develops reagent technologies for cell-based and in vivo applications.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.